Objectives: Central hypothyroidism (CeH) is a rare form of hypothyroidism characterized by insufficient thyroid stimulation due to disturbed pituitary and/or hypothalamic functioning. Due to its origin and the whole clinical context, CeH represents a challenging condition in clinical practice as it is characterized by suboptimal accuracy of clinical and biochemical parameters for diagnosis and management. Since no expert consensus or guidance for this condition is currently available, a task force of experts received the commitment from the European Thyroid Association (ETA) to prepare this document based on the principles of clinical evidence. Study Design: The task force started to work in February 2017 and after a careful selection of appropriate references (cohort studies, case reports, expert opinions), a preliminary presentation and live discussion during the 2017 ETA meeting, and several revision rounds, has prepared a list of recommendations to support the diagnosis and management of patients with CeH. Results: Due to the particular challenges of this rare condition in the different ages, the target users of this guidance are pediatric and adult endocrinologists. Experts agreed on the need to recognize and treat overt CeH at all ages, whereas treatment of milder forms may be dispensable in the elderly (> 75 years). Conclusions: Despite the lack of randomized controlled clinical trials, the experts provide 34 recommendations supported by variable levels of strength that should improve the quality of life of the affected patients and reduce the metabolic and hormonal consequences of inadequate management.

Keywords:
Central hypothyroidism, Thyroxine, Thyrotropin, TRH, Pituitary, Thyroid, Subclinical hypothyroidism, Guidelines, Hormone replacement therapy
1.
Persani L: Clinical review: central hypothyroidism: pathogenic, diagnostic, and therapeutic challenges. J Clin Endocrinol Metab 2012; 97: 3068–3078.
2.
Persani L, Beck-Peccoz P: Central hypothyroidism; in Braverman LE, Cooper D (ed): Werner and Ingbar’s The Thyroid: A Fundamental and Clinical Text, ed 10. Lippincott Williams and Wilkins/Wolters Kluwer Health, Philadelphia, 2012, pp 560–568.
3.
Zwaveling-Soonawala N, van Trotsenburg AS, Verkerk PH: The severity of congenital hypothyroidism of central origin should not be underestimated. J Clin Endocrinol Metab 2015; 100:E297–E300.
4.
Price A, Weetman AP: Screening for central hypothyroidism is unjustified. Br Med J 2001; 322: 798.
5.
Baloch Z, Carayon P, Conte-Devolx B, Demers LM, Feldt-Rasmussen U, Henry JF, LiVosli VA, Niccoli-Sire P, John R, Ruf J, Smyth PP, Spencer CA, Stockigt JR: Laboratory medicine practice guidelines. Laboratory support for the diagnosis and monitoring of thyroid disease. Thyroid 2003; 13: 3–126.
6.
Wardle CA, Fraser WD, Squire CR: Pitfalls in the use of thyrotropin concentration as a first-line thyroid-function test. Lancet 2001; 357: 1013–1014.
7.
Baquedano MS, Ciaccio M, Dujovne N, Herzovich V, Longueira Y, Warman DM, Rivarola MA, Belgorosky A: Two novel mutations of the TSH-beta subunit gene underlying congenital central hypothyroidism undetectable in neonatal TSH screening. J Clin Endocrinol Metab 2010; 95:E98–E103.
8.
Kempers MJ, van der Sluijs Veer L, Nijhuis-van der Sanden RW, Lanting CI, Kooistra L, Wiedijk BM, Last BF, de Vijlder JJ, Grootenhuis MA, Vulsma T: Neonatal screening for congenital hypothyroidism in the Netherlands: cognitive and motor outcome at 10 years of age. J Clin Endocrinol Metab 2007; 92: 919–924.
9.
Nebesio TD, McKenna MP, Nabhan ZM, Eugster EA: Newborn screening results in children with central hypothyroidism. J Pediatr 2010; 156: 990–993.
10.
Adachi M, Soneda A, Asakura Y, Muroya K, Yamagami Y, Hirahara F: Mass screening of newborns for congenital hypothyroidism of central origin by free thyroxine measurement of blood samples on filter paper. Eur J Endocrinol 2012; 166: 829–838.
11.
Bonomi M, Busnelli M, Beck-Peccoz P, Costanzo D, Antonica F, Dolci C, Pilotta A, Buzi F, Persani L: A family with complete resistance to thyrotropin-releasing hormone. N Engl J Med 2009; 360: 731–734.
12.
Sun Y, Bak B, Schoenmakers N, van Trotsenburg AS, Oostdijk W, Voshol P, Cambridge E, White JK, le Tissier P, Gharavy SN, Martinez-Barbera JP, Stokvis-Brantsma WH, Vulsma T, Kempers MJ, Persani L, Campi I, Bonomi M, Beck-Peccoz P, Zhu H, Davis TM, Hokken-Koelega AC, Del Blanco DG, Rangasami JJ, Ruivenkamp CA, Laros JF, Kriek M, Kant SG, Bosch CA, Biermasz NR, Appelman-Dijkstra NM, Corssmit EP, Hovens GC, Pereira AM, den Dunnen JT, Wade MG, Breuning MH, Hennekam RC, Chatterjee K, Dattani MT, Wit JM, Bernard DJ: Loss-of-function mutations in IGSF1 cause an X-linked syndrome of central hypothyroidism and testicular enlargement. Nat Genet 2012; 44: 1375–1381.
13.
Heinen CA, Losekoot M, Sun Y, Watson PJ, Fairall L, Joustra SD, Zwaveling-Soonawala N, Oostdijk W, van den Akker EL, Alders M, Santen GW, van Rijn RR, Dreschler WA, Surovtseva OV, Biermasz NR, Hennekam RC, Wit JM, Schwabe JW, Boelen A, Fliers E, van Trotsenburg AS: Mutations in TBL1X are associated with central hypothyroidism. J Clin Endocrinol Metab 2016; 101: 4564–4573.
14.
Faglia G, Bitensky L, Pinchera A, Ferrari C, Paracchi A, Beck-Peccoz P, Ambrosi B, Spada A: Thyrotropin secretion in patients with central hypothyroidism: evidence for reduced biological activity of immunoreactive thyrotropin. J Clin Endocrinol Metab 1979; 48: 989–998.
15.
Beck-Peccoz P, Amr S, Menezes-Ferreira MM, Faglia G, Weintraub BD: Decreased receptor binding of biologically inactive thyrotropin in central hypothyroidism. Effect of treatment with thyrotropin-releasing hormone. N Engl J Med 1985; 312: 1085–1090.
16.
Horimoto M, Nishikawa M, Ishihara T, Yoshikawa N, Yoshimura M, Inada M: Bioactivity of thyrotropin (TSH) in patients with central hypothyroidism: comparison between in vivo 3,5,3′-triiodothyronine response to TSH and in vitro bioactivity of TSH. J Clin Endocrinol Metab 1995; 80: 1124–1128.
17.
Persani L, Ferretti E, Borgato S, Faglia G, Beck-Peccoz P: Circulating thyrotropin bioactivity in sporadic central hypothyroidism. J Clin Endocrinol Metab 2000; 85: 3631–3635.
18.
Persani L, Tonacchera M, Beck-Peccoz P, Vitti P, Mammoli C, Chiovato L, Elisei R, Faglia G, Ludgate M, Vassart G: Measurement of cAMP accumulation in Chinese hamster ovary cells transfected with the recombinant human TSH receptor (CHO-R): a new bioassay for human thyrotropin. J Endocrinol Invest 1993; 16: 511–519.
19.
Guyatt GH, Oxman AD, Vist GE, et al; GRADE Working Group: GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. Br Med J 2008; 336: 924–926.
20.
Swiglo BA, Murad MH, Schunemann HJ, Kunz R, Vigersky RA, Guyatt GH, Montori VM: A case for clarity, consistency, and helpfulness: state-of-the-art clinical practice guidelines in endocrinology using the grading of recommendations, assessment, development, and evaluation system. J Clin Endocrinol Metab 2008; 93: 666–673.
21.
Brouwers MC, Kho ME, Browman GP, et al: AGREE II: Advancing guideline development, reporting and evaluation in healthcare. CMAJ 2010; 182:E839–E842.
22.
Kapelari K, Kirchlechner C, Högler W, Schweitzer K, Virgolini I, Moncayo R: Pediatric reference intervals for thyroid hormone levels from birth to adulthood: a retrospective study. BMC Endocr Disord 2008; 8: 15.
23.
Park SY, Kim HI, Oh HK, Kim TH, Jang HW, Chung JH, Shin MH, Kim SW: Age- and gender-specific reference intervals of TSH and free T4 in an iodine-replete area: data from Korean National Health and Nutrition Examination Survey IV (2013–2015). PLoS One 2018; 13:e0190738.
24.
Ferretti E, Persani L, Jaffrain-Rea ML, Giambona S, Tamburrano G, Beck-Peccoz P: Evaluation of the adequacy of levothyroxine replacement therapy in patients with central hypothyroidism. J Clin Endocrinol Metab 1999; 84: 924–929.
25.
Alexopoulou O, Beguin C, De Nayer P, Maiter D: Clinical and hormonal characteristics of central hypothyroidism at diagnosis and during follow-up in adult patients. Eur J Endocrinol 2004; 150: 1–8.
26.
Bonomi M, Proverbio MC, Weber G, Chiumello G, Beck-Peccoz P, Persani L: Hyperplastic pituitary gland, high serum glycoprotein hormone alpha-subunit, and variable circulating thyrotropin (TSH) levels as hallmark of central hypothyroidism due to mutations of the TSH beta gene. J Clin Endocrinol Metab 2001; 86: 1600–1604.
27.
Miyai K: Congenital thyrotropin deficiency – from discovery to molecular biology, postgenome and preventive medicine. Endocr J 2007; 54: 191–203.
28.
Collu R, Tang J, Castagne J, Lagace G, Masson N, Huot C, Deal C, Delvin E, Faccenda E, Eidne KA, Van Vliet G: A novel mechanism for isolated central hypothyroidism: inactivating mutations in the thyrotropin-releasing hormone receptor gene. J Clin Endocrinol Metab 1997; 82: 1561–1565.
29.
Koulouri O, Nicholas AK, Schoenmakers E, Mokrosinski J, Lane F, Cole T, Kirk J, Farooqi IS, Chatterjee VK, Gurnell M, Schoenmakers N: A novel thyrotropin-releasing hormone receptor missense mutation (P81R) in central congenital hypothyroidism. J Clin Endocrinol Metab 2016; 101: 847–851.
30.
Garcia M, Gonzalez de Buitrago J, Jimenez-Roses M, Pardo L, Hinkle PM, Moreno JC: Central hypothyroidism due to a TRHR mutation causing impaired ligand affinity and transactivation of Gq. J Clin Endocrinol Metab 2017; 102: 2433–2442.
31.
Joustra SD, van der Plas EM, Goede J, Oostdijk W, Delemarre-van de Waal HA, Hack WW, van Buuren S, Wit JM: New reference charts for testicular volume in Dutch children and adolescents allow the calculation of standard deviation scores. Acta Paediatr 2015; 104:e271–e278.
32.
Joustra SD, Heinen CA, Schoenmakers N, Bonomi M, Ballieux BE, Turgeon MO, Bernard DJ, Fliers E, van Trotsenburg AS, Lose­koot M, Persani L, Wit JM, Biermasz NR, Pereira AM, Oostdijk W: IGSF1 deficiency: lessons from an extensive case series and recommendations for clinical management. J Clin Endocrinol Metab 2016; 101: 1627–1636.
33.
Zwaveling-Soonawala N, Naafs JC, Verkerk PH, van Trotsenburg ASP: Mortality in children with early detected congenital central hypothyroidism. J Clin Endocrinol Metab 2018, Epub ahead of print.
34.
Yamada M, Mori M: Mechanisms related to the pathophysiology and management of central hypothyroidism. Nat Clin Pract Endocrinol Metab 2008; 4: 683–694.
35.
Pfaffle R, Klammt J: Pituitary transcription factors in the aetiology of combined pituitary hormone deficiency. Best Pract Res Clin Endocrinol Metab 2011; 25: 43–60.
36.
Persani L, Bonomi M: The multiple genetic causes of central hypothyroidism. Best Pract Res Clin Endocrinol Metab 2017; 31: 255–263.
37.
Giri D, Vignola ML, Gualtieri A, Scagliotti V, McNamara P, Peak M, Didi M, Gaston-Massuet C, Senniappan S: Novel FOXA2 mutation causes hyperinsulinism, hypopituitarism with craniofacial and endoderm-derived organ abnormalities. Hum Mol Genet 2017; 26: 4315–4326.
38.
Haugen BR: Drugs that suppress TSH or cause central hypothyroidism. Best Pract Res Clin Endocrinol Metab 2009; 23: 793–800.
39.
Russo M, Scollo C, Pellegriti G, Cotta OR, Squatrito S, Frasca F, Cannavò S, Gullo D: Mitotane treatment in patients with adrenocortical cancer causes central hypothyroidism. Clin Endocrinol (Oxf) 2016; 84: 614–6199.
40.
Neumann S, Raaka BM, Gershengorn MC: Constitutively active thyrotropin and thyrotropin-releasing hormone receptors and their inverse agonists. Methods Enzymol 2010; 485: 147–160.
41.
Barbesino G, Sluss PM, Caturegli P: Central hypothyroidism in a patient with pituitary autoimmunity: evidence for TSH-independent thyroid hormone synthesis. J Clin Endocrinol Metab 2012; 97: 345–350.
42.
Lee KO, Persani L, Tan M, Sundram FX, Beck-Peccoz P: Thyrotropin with decreased biological activity, a delayed consequence of cranial irradiation for nasopharyngeal carcinoma. J Endocrinol Invest 1995; 18: 800–805.
43.
Rose SR: Cranial irradiation and central hypothyroidism. Trends Endocrinol Metab 2001; 12: 97–104.
44.
Rose SR, Lustig RH, Pitukcheewanont P, Broome DC, Burghen GA, Li H, Hudson MM, Kun LE, Heideman RL: Diagnosis of hidden central hypothyroidism in survivors of childhood cancer. J Clin Endocrinol Metab 1999; 84: 4472–4479.
45.
Darzy KH, Shalet SM: Circadian and stimulated thyrotropin secretion in cranially irradiated adult cancer survivors. J Clin Endocrinol Metab 2005; 90: 6490–6497.
46.
Jostel A, Ryder WD, Shalet SM: The use of thyroid function tests in the diagnosis of hypopituitarism: definition and evaluation of the TSH Index. Clin Endocrinol (Oxf) 2009; 71: 529–534.
47.
Doin FC, Rosa-Borges M, Martins MR, Moisés VA, Abucham J: Diagnosis of subclinical central hypothyroidism in patients with hypothalamic-pituitary disease by Doppler echocardiography. Eur J Endocrinol 2012; 166: 631–640.
48.
Persani L, de Filippis T, Colombo C, Gentilini D: Genetics in endocrinology: genetic diagnosis of endocrine diseases by NGS: novel scenarios and unpredictable risks. Eur J Endocrinol 2018, Epub ahead of print.
49.
Slawik M, Klawitter B, Meiser E, Schories M, Zwermann O, Borm K, Peper M, Lubrich B, Hug MJ, Nauck M, Olschewski M, Beuschlein F, Reincke M: Thyroid hormone replacement for central hypothyroidism: a randomized controlled trial comparing two doses of thyroxine (T4) with a combination of T4 and triiodothyronine. J Clin Endocrinol Metab 2007; 92: 4115–4122.
50.
Jonklaas J, Bianco AC, Bauer AJ, Burman KD, Cappola, AR, Celi FS, Cooper DS, Kim BW, Peeters RP, Rosenthal MS, Sawka AM: Guidelines for the treatment of hypothyroidism. Thyroid 2014; 24: 1670–1751.
51.
Wiersinga WM, Duntas L, Fadeyev V, Nygaard B, Vanderpump MP: 2012 ETA guidelines: the use of L-T4 + L-T3 in the treatment of hypothyroidism. Eur Thyroid J 2012; 1: 55–71.
52.
Aleksander P, Bruckner-Spieler M, Stohr AM, Lankes E, Kuhnen P, Schnabel D, Ernert A, Stablein W, Craig ME, Blankenstein O, Gruters A, Krude H: Mean high dose L-thyroxine treatment is efficient and safe to achieve a normal IQ in young adult patients with congenital hypothyroidism. J Clin Endocrinol Metab 2018; 103: 1459–1469.
53.
Helfand M, Crapo LM: Monitoring therapy in patients taking levothyroxine. Ann Int Med 1990; 113: 450–454.
54.
Koch CA, Sarlis NJ: The spectrum of thyroid diseases in childhood and its evolution during transition to adulthood: natural history, diagnosis, differential diagnosis and management. J Endocrinol Invest 2001; 24: 659–675.
55.
Feldt-Rasmussen U, Klose M: Central hypothyroidism and its role for cardiovascular risk factors in hypopituitary patients. Endocrine 2016; 54: 15–23.
56.
Iverson JF, Mariash CN: Optimal free thyroxine levels for thyroid hormone replacement in hypothyroidism. Endocr Pract 2008; 14: 550–555.
57.
Beck-Peccoz P: Treatment of central hypothyroidism. Clin Endocrinol 2011; 74: 671–672.
58.
Koulouri O, Auldin MA, Agarwal R, Kieffer V, Robertson C, Falconer Smith J, Levy MJ, Howlett TA: Diagnosis and treatment of hypothyroidism in TSH deficiency compared to primary thyroid disease: pituitary patients are at risk of under-replacement with levothyroxine. Clin Endocrinol 2011; 74: 744–749.
59.
Leger J, Olivieri A, Donaldson M, Torresani T, Krude H, van Vliet G, Polak M, Butler G: European Society for Paediatric Endocrinology consensus guidelines on screening, diagnosis, and management of congenital hypothyroidism. Horm Res Paediatr 2014; 81: 80–103.
60.
Hirata Y, Fukuoka H, Iguchi G, Iwahashi Y, Fujita Y, Hari Y, Iga M, Nakajima S, Nishimoto Y, Mukai M, Hirota Y, Sakaguchi K, Ogawa W, Takahashi Y: Median-lower normal levels of serum thyroxine are associated with low triiodothyronine levels and body temperature in patients with central hypothyroidism. Eur J Endocrinol 2015; 173: 247–256.
61.
Carrozza V, Csako G, Yanovski JA, Skarulis MC, Nieman L, Wesley R, Pucino F: Levothyroxine replacement therapy in central hypothyroidism: a practice report. Pharmacotherapy 1999; 19: 349–355.
62.
Shimon I, Cohen O, Lubetsky A, Olchovsky D: Thyrotropin suppression by thyroid hormone replacement is correlated with thyroxine level normalization in central hypothyroidism. Thyroid 2002; 12: 823–827.
63.
Beck-Peccoz P, Rodari G, Giavoli C, Lania A: Central hypothyroidism – a neglected thyroid disorder. Nat Rev Endocrinol 2017; 13: 588–598.
64.
Benaglia L, Busnelli A, Somigliana E, Leonardi M, Vannucchi G, De Leo S, Fugazzola L, Ragni G, Fedele L: Incidence of elevation of serum thyroid-stimulating hormone during controlled ovarian hyperstimulation for in vitro fertilization. Eur J Obstet Gynecol Reprod Biol 2014; 173: 53–57.
65.
Arafah BM: Increased need for thyroxine in women with hypothyroidism during estrogen therapy. N Engl J Med 2001; 344: 1743–1749.
© 2018 European Thyroid Association Published by S. Karger AG, Basel
2018
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.